This file is part of IDEAS, which uses RePEc data

Wolters Kluwer Health | Adis

PharmacoEconomics

Contact information of Wolters Kluwer Health | Adis:
Web page: http://pharmacoeconomics.adisonline.com/

To be notified about new items in this series: Register for eTOC http://pharmacoeconomics.adisonline.com/pt/re/phe/etocs.htm (see also NEP)
Download restrictions: Pay per view
Editor:
For technical questions regarding this series, please contact (Remco Bouckaert)
Series handle: repec:wkh:phecon

More pages of listings: 0|1|2|3|4|5

2009, Volume 27, Issue 12

979-982 Swimming Upstream: Comparative Effectiveness Research in the US
by Jeremy A. Greene [Downloadable! (restricted)]
983-989 Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected
by Allan Wailoo & Aki Tsuchiya & Christopher McCabe [Downloadable! (restricted)]
991-1004 Cost Effectiveness of Herpes Zoster Vaccine in Canada
by Mehdi Najafzadeh & Carlo A. Marra & Eleni Galanis & David M. Patrick & David M. Patrick [Downloadable! (restricted)]
1005-1016 Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
by Tracy A. Lieu & G. Thomas. Ray & Ismael R. Ortega-Sanchez & Ken Kleinman & Donna Rusinak & Lisa A. Prosser [Downloadable! (restricted)]
1017-1029 Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
by Aline Gauthier & Andrea Manca & Susan Anton [Downloadable! (restricted)]
1031-1044 Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
by David R. Rappange & Werner B.F. Brouwer & Rudolf T. Hoogenveen & Pieter H.M. Van Baal [Downloadable! (restricted)]
1045-1056 Accounting for the Development of Antibacterial Resistance in the Cost Effectiveness of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in the UK
by Jeroen P. Jansen & Ritesh Kumar & Yehuda Carmeli [Downloadable! (restricted)]

2009, Volume 27, Issue 11

887-889 Developing Nations Special Issue
by Mendel E. Singer [Downloadable! (restricted)]
891-901 The Future of Health Technology Assessment in Healthcare Decision Making in Asia
by Bong-Min Yang [Downloadable! (restricted)]
903-917 Cost Effectiveness in Low- and Middle-Income Countries: A Review of the Debates Surrounding Decision Rules
by Samuel D. Shillcutt & Damian G. Walker & Catherine A. Goodman & Anne J. Mills [Downloadable! (restricted)]
919-929 Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region
by Federico Augustovski & Cynthia Iglesias & Andrea Manca & Michael Drummond & Adolfo Rubinstein & Sebastin Garca. Mart [Downloadable! (restricted)]
931-945 Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program
by Sripen Tantivess & Yot Teerawattananon & Anne Mills [Downloadable! (restricted)]
947-961 Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries: An Observational Study of Breast Cancer Chemotherapy in Taiwan
by Ya-Chen Tina. Shih & I-Wen Pan & Yi-Wen Tsai [Downloadable! (restricted)]
963-973 Cost Effectiveness of Facility-Based Care, Home-Based Care and Mobile Clinics for Provision of Antiretroviral Therapy in Uganda
by Joseph B. Babigumira & Ajay K. Sethi & Kathleen A. Smyth & Mendel E. Singer [Downloadable! (restricted)]

2009, Volume 27, Issue 10

793-795 New Anticoagulants for the Prevention of Deep Venous Thrombosis: Time to Consider Cost Effectiveness?
by Stavros Apostolakis & Eduard Shantsila & Gregory Y.H. Lip [Downloadable! (restricted)]
797-806 Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
by John A. Vernon & Robert Goldberg & Joseph Golec [Downloadable! (restricted)]
807-827 Budget-Impact Analyses: A Critical Review of Published Studies
by Ewa Orlewska & Laszlo Gulcsi [Downloadable! (restricted)]
829-846 A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
by Laura McCullagh & Lesley Tilson & Cathal Walsh & Michael Barry [Downloadable! (restricted)]
861-872 30 Years of Pharmaceutical Cost-Utility Analyses: Growth, Diversity and Methodological Improvement
by Peter J. Neumann & Chi-Hui Fang & Joshua T. Cohen [Downloadable! (restricted)]
873-886 Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
by Peng Liubao & Wan Xiaomin & Tan Chongqing & Jon Karnon & Chen Gannong & Li Jianhe & Cui Wei & Luo Xia & Cao Junhua [Downloadable! (restricted)]

2009, Volume 27, Issue 9

705-712 The Role of Patient Preferences in Cost-Effectiveness Analysis: A Conflict of Values?
by John E. Brazier & Simon Dixon & Julie Ratcliffe [Downloadable! (restricted)]
713-723 Methods for Measuring Temporary Health States for Cost-Utility Analyses
by Davene R. Wright & Eve Wittenberg & J. Shannon. Swan & Rebecca A. Miksad & Lisa A. Prosser [Downloadable! (restricted)]
735-744 A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US
by Sandra L. Tunis [Downloadable! (restricted)]
745-753 Comparing Three Software Tools for Implementing Markov Models for Health Economic Evaluations
by Petra Menn & Rolf Holle [Downloadable! (restricted)]
755-765 The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching: The Case of ESA Costs for the Treatment of Chemotherapy-Induced Anaemia
by Daniel Polsky & Daria Eremina & Gregory Hess & Jerrold Hill & Scott Hulnick & Adam Roumm & Joanna L. Whyte & Joel Kallich [Downloadable! (restricted)]
767-779 Utilities of the EQ-5D: Transferable or Not?
by Saskia Knies & Silvia M.A.A. Evers & Math J.J.M. Candel & Johan L. Severens & Andr J.H.A. Ament [Downloadable! (restricted)]
781-792 Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans
by Ronald R. White & Greg Lenhart & Puneet K. Singhal & Ralph P. Insinga & Robbin F. Itzler & James M. Pellissier & Arthur W. Segraves [Downloadable! (restricted)]

2009, Volume 27, Issue 8

623-625 Legal and Economic Perspectives Concerning US Government Investigations of Alleged Off-Label Promotion by Drug Manufacturers
by Paul E. Kalb & Paul E. Greenberg [Downloadable! (restricted)]
627-634 Case-Control Studies in Pharmacoeconomic Research: An Overview
by J. Jaime. Caro & Krista F. Huybrechts [Downloadable! (restricted)]
635-643 Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations
by Dyfrig A. Hughes & Lesley Tilson & Michael Drummond [Downloadable! (restricted)]
645-655 A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes
by Gianluca Baio & Pierluigi Russo [Downloadable! (restricted)]
657-679 Economic Burden of Follicular Non-Hodgkin's Lymphoma
by Talia Foster & Jeffrey D. Miller & Mark E. Boye & Mason W. Russell [Downloadable! (restricted)]
681-691 The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US
by Jasmina I. Ivanova & Howard G. Birnbaum & Seth Samuels & Matthew Davis & Amy L. Phillips & Dennis Meletiche [Downloadable! (restricted)]
693-704 Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women
by Andrej Rasch & Jan-Marc Hodek & Claus Runge & Wolfgang Greiner [Downloadable! (restricted)]

2009, Volume 27, Issue 7

529-531 Is it Time for Reporting Guidelines for Calibration Methods?
by Scott B. Cantor [Downloadable! (restricted)]
533-545 Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
by Natasha K. Stout & Amy B. Knudsen & Chung Yin. Kong & Pamela M. McMahon & G. Scott. Gazelle [Downloadable! (restricted)]
547-559 Societal and Patient Burden of Fibromyalgia Syndrome
by Lieven Annemans & Katell Le Lay & Charles Taeb [Downloadable! (restricted)]
561-570 Economic Evaluations in the EURONHEED: A Comparative Analysis
by Florencia Hutter & Fernando Antoanzas [Downloadable! (restricted)]
571-584 Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease
by Yaroslav Winter & Sonja von Campenhausen & Georgy Popov & Jens P. Reese & Jens Klotsche & Kai Btzel & Eugene Gusev & Wolfgang H. Oertel & Richard Dodel & Alla Guekht [Downloadable! (restricted)]
585-595 Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome
by Jaime Latour-Perez & Eva de-Miguel-Balsa [Downloadable! (restricted)]
597-608 Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan
by Takeru Shiroiwa & Takashi Fukuda & Kojiro Shimozuma & Yasuo Ohashi & Kiichiro Tsutani [Downloadable! (restricted)]
609-621 Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease
by Andrew P. Yu & Scott Johnson & Si-Tien Wang & Pavel Atanasov & Jackson Tang & Eric Wu & Jingdong Chao & Parvez M. Mulani [Downloadable! (restricted)]

2009, Volume 27, Issue 6

439-450 Cost Effectiveness of Influenza Vaccination in Older Adults: A Critical Review of Economic Evaluations for the 50- to 64-Year Age Group
by Anthony T. Newall & Heath Kelly & Stuart Harsley & Paul A. Scuffham [Downloadable! (restricted)]
451-464 Pharmacoeconomic Considerations in Treating Actinic Keratosis
by Marjorie V. Neidecker & Mary Lynn. Davis-Ajami & Rajesh Balkrishnan & Steven R. Feldman [Downloadable! (restricted)]
465-477 Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health: The Case of Chronic Obstructive Pulmonary Disease
by Maureen P.M.H. Rutten-van Mlken & Martine Hoogendoorn & Leida M. Lamers [Downloadable! (restricted)]
479-490 Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus: Results from a US Claims Data Analysis
by Elise M. Pelletier & Boyung Shim & Rami Ben-Joseph & J. Jaime. Caro [Downloadable! (restricted)]
491-505 Converting the SF-12 into the EQ-5D: An Empirical Comparison of Methodologies
by Ling-Hsiang Chuang & Paul Kind [Downloadable! (restricted)]
507-517 Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants
by Howard G. Birnbaum & Rym Ben-Hamadi & Paul E. Greenberg & Matthew Hsieh & Jackson Tang & Camille Reygrobellet [Downloadable! (restricted)]
519-528 How to Deal with Cost Differences at Baseline
by Antoinette D.I. van Asselt & Ghislaine A.P.G. van Mastrigt & Carmen D. Dirksen & Arnoud Arntz & Johan L. Severens & Alfons G.H. Kessels [Downloadable! (restricted)]

2009, Volume 27, Issue 5

355-363 The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics
by Joseph Cook & Graeme Hunter & John A. Vernon [Downloadable! (restricted)]
365-378 The Cost and Impact of Health Conditions on Presenteeism to Employers: A Review of the Literature
by Alyssa B. Schultz & Chin-Yu Chen & Dee W. Edington [Downloadable! (restricted)]
379-389 Costing Infectious Disease Outbreaks for Economic Evaluation: A Review for Hepatitis A
by Jeroen Luyten & Philippe Beutels [Downloadable! (restricted)]
391-403 The Cost of Dementia in Europe: A Review of the Evidence, and Methodological Considerations
by Linus Jnsson & Anders Wimo [Downloadable! (restricted)]
405-419 Utility Assessment in Patients with Mental Disorders: Validity and Discriminative Ability of the Time Trade-Off Method
by Hans-Helmut Knig & Oliver H. Gnther & Matthias C. Angermeyer & Christiane Roick [Downloadable! (restricted)]
421-430 Outcomes Associated with Initial versus Later Vancomycin Use in Patients with Complicated Skin and Skin-Structure Infections
by Kamal M.F. Itani & Kasem S. Akhras & Robert Stellhorn & Alvaro Quintana & David Budd & Sanjay Merchant [Downloadable! (restricted)]
431-432 Pharmaceutical Risk-Sharing Agreements
by Afschin Gandjour [Downloadable! (restricted)]
433-434 The Author's Reply
by Lieven Annemans, on behalf of the authors [Downloadable! (restricted)]
435-438 Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs
by Brian Godman & Ulrich Schwabe & Gisbert Selke & Bjrn Wettermark [Downloadable! (restricted)]
433 Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
by Irina Cleemput & Nancy Thiry [Downloadable! (restricted)]

2009, Volume 27, Issue 4

267-279 Economic and Human Costs of Restless Legs Syndrome
by Thomas Reinhold & Falk Mller-Riemenschneider & Stefan N. Willich & Bernd Brggenjrgen [Downloadable! (restricted)]
281-297 Reviewing the Cost Effectiveness of Rotavirus Vaccination: The Importance of Uncertainty in the Choice of Data Sources
by Joke Bilcke & Philippe Beutels [Downloadable! (restricted)]
299-312 Willingness to Pay for Cancer Prevention
by Timothy L. Hunt & Bryan R. Luce & Matthew J. Page & Robin Pokrzywinski [Downloadable! (restricted)]
313-327 Cost Effectiveness of Drug-Eluting Stents In Belgian Practice: Healthcare Payer Perspective
by Mattias Neyt & Chris De Laet & Annemieke De Ridder & Hans Van Brabandt [Downloadable! (restricted)]
329-339 Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder: Results from the MATRIX Study
by Laura T. Pizzi & Amy Talati & Eric Gemmen & Naomi V. Dahl & Thomas J. Bunz & Peter K. Sand [Downloadable! (restricted)]
341-354 Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response: A Decision Analysis Based on German Guidelines
by Uwe Siebert & Gaby Sroczynski & Pamela Aidelsburger & Siegbert Rossol & Jurgen Wasem & Michael P. Manns & John G. McHutchison & John B. Wong [Downloadable! (restricted)]

2009, Volume 27, Issue 3

179-188 Costing and Cost Analysis in Randomized Controlled Trials: Caveat Emptor
by Daniel Polsky & Henry Glick [Downloadable! (restricted)]
189-198 Cost of Illness of Glaucoma: A Critical and Systematic Review
by Richard G. Fiscella & Jeff Lee & Elizabeth J.H. Davis & John Walt [Downloadable! (restricted)]
199-209 The Costs of Treating Breast Cancer in the US: A Synthesis of Published Evidence
by Jonathan D. Campbell & Scott D. Ramsey [Downloadable! (restricted)]
211-219 Preferences of GPs and Patients for Preventive Osteoporosis Drug Treatment: A Discrete-Choice Experiment
by Esther W. de Bekker-Grob & Marie-Louise Essink-Bot & Willem Jan. Meerding & Bart W. Koes & Ewout W. Steyerberg [Downloadable! (restricted)]
221-230 The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone: Results from ASCOT1
by Peter Lindgren & Martin Buxton & Thomas Kahan & Neil R. Poulter & Bjrn Dahlf & Peter S. Sever & Hans Wedel & Bengt Jonsson [Downloadable! (restricted)]
231-245 Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
by Lieven Annemans & Vanessa Rmy & James Oyee & Nathalie Largeron [Downloadable! (restricted)]
247-261 Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan
by Ataru Igarashi & Hiroki Takuma & Takashi Fukuda & Kiichiro Tsutani [Downloadable! (restricted)]
263-264 Methods of Economic Evaluation for the German Statutory Healthcare System
by J. Jaime. Caro [Downloadable! (restricted)]

2009, Volume 27, Issue 2

91-93 Controlling Cervical Cancer
by Maurizio Bonati & Silvio Garattini [Downloadable! (restricted)]
95-112 Neuropathic Pain: Quality-of-Life Impact, Costs and Cost Effectiveness of Therapy
by Alec B. OConnor [Downloadable! (restricted)]
113-125 Economics of Treatments for Non-Small Cell Lung Cancer
by Christos Chouaid & Kukovi Atsou & Gilles Hejblum & Alain Vergnenegre [Downloadable! (restricted)]
127-147 Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine: A Systematic Review
by Fawziah Marra & Karine Cloutier & Bridgette Oteng & Carlo Marra & Gina Ogilvie [Downloadable! (restricted)]
149-158 Willingness to Pay for a Treatment for Pain in Multiple Sclerosis
by Michael Iskedjian & Olivier Desjardins & Charles Piwko & Basil Bereza & Barbara Jaszewski & Thomas R. Einarson [Downloadable! (restricted)]
159-165 Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV
by Kit N. Simpson & Alvin Strassburger & Walter J. Jones & Birgitta Dietz & Rukmini Rajagopalan [Downloadable! (restricted)]
167-177 Challenges in Merging Medicaid and Medicare Databases to Obtain Healthcare Costs for Dual-Eligible Beneficiaries: Using Diabetes as an Example
by Cecilia M. Prela & Greg A. Baumgardner & Gayle E. Reiber & Lynne V. McFarland & Charles Maynard & Nancy Anderson & Matthew Maciejewski [Downloadable! (restricted)]

2009, Volume 27, Issue 1

1-4 Methods of Economic Evaluation for the German Statutory Healthcare System
by Hengjin Dong [Downloadable! (restricted)]
5-10 The Applicability and Generalizability of Findings from Clinical Trials for Health-Policy Decisions
by Nick Freemantle & Franz Hessel [Downloadable! (restricted)]
11-24 Is Medication Review by Primary-Care Pharmacists for Older People Cost Effective?: A Narrative Review of the Literature, Focusing on Costs and Benefits
by Arnold G. Zermansky & Jonathan Silcock [Downloadable! (restricted)]
25-37 Statin Therapy in Rheumatoid Arthritis: A Cost-Effectiveness and Value-of-Information Analysis
by Nick Bansback & Roberta Ara & Sue Ward & Aslam Anis & Hyon K. Choi [Downloadable! (restricted)]
39-53 Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications
by Shien Guo & Duygu Bozkaya & Alexandra Ward & Judith A. O'Brien & Khajak Ishak & Randy Bennett & Ahmad Al-Sabbagh & Dennis M. Meletiche [Downloadable! (restricted)]
55-68 Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma
by Philippe Fagnoni & Noel Milpied & Samuel Limat & Eric Deconinck & Virginie Nerich & Charles Foussard & Philippe Colombat & Jean-Luc Harousseau & Marie-Christine Woronoff-Lemsi [Downloadable! (restricted)]
69-80 Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach
by Annemieke De Ridder & Diana De Graeve [Downloadable! (restricted)]
81-90 Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data
by Ulf-G Gerdtham & Philip Clarke & Alison Hayes & Soffia Gudbjornsdottir [Downloadable! (restricted)]

2008, Volume 26, Issue 12

983-985 Acknowledgement
by Adis International Limited [Downloadable! (restricted)]
987-989 Does `NICE blight' exist, and if so, why?
by Alan Haycox [Downloadable! (restricted)]
991-1003 Modelling Downstream Effects in the Presence of Technological Change
by Duncan Mortimer [Downloadable! (restricted)]
1005-1017 Measuring US Pharmaceutical Industry R&D Spending
by Joseph Golec & John Vernon [Downloadable! (restricted)]
1019-1035 Management and Prevention of Diabetic Foot Ulcers and Infections: A Health Economic Review
by Ivy Chow & Elkin V. Lemos & Thomas R. Einarson [Downloadable! (restricted)]
1037-1043 Single Technology Appraisals by NICE: Are They Delivering Faster Guidance to the NHS?
by Leela Barham [Downloadable! (restricted)]
1045-1064 A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
by Alec B. O'Connor & Katia Noyes & Robert G. Holloway [Downloadable! (restricted)]
1065 Book Review
by Adis International Limited [Downloadable! (restricted)]

2008, Volume 26, Issue 11

895-898 Loss Aversion and Cost Effectiveness of Healthcare Programmes
by Afschin Gandjour [Downloadable! (restricted)]
899-900 Loss Aversion and Cost Effectiveness of Healthcare Programmes: Whose Aversion Counts Anyway?
by Johan L. Severens [Downloadable! (restricted)]
901-910 Methods for the Meta-Analysis of Willingness-to-Pay Data: An Overview
by George Van Houtven [Downloadable! (restricted)]
911-924 The Impact of Influenza on Working Days Lost: A Review of the Literature
by Martin Keech & Paul Beardsworth [Downloadable! (restricted)]
925-935 A Review of Health-Utility Data for Osteoarthritis: Implications for Clinical Trial-Based Evaluation
by Hirsch S. Ruchlin & Ralph P. Insinga [Downloadable! (restricted)]
937-949 A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
by D. Eldon Spackman & David L. Veenstra [Downloadable! (restricted)]
951-967 Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients
by Gerardo Machnicki & Jean-Francois Ricci & Daniel C. Brennan & Mark A. Schnitzler [Downloadable! (restricted)]
969-981 Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data
by Alan G. Wade & Jose-Luis Fernandez & Clement Francois & Karina Hansen & Natalya Danchenko & Nicolas Despiegel [Downloadable! (restricted)]

2008, Volume 26, Issue 10

807-809 Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing
by Steven Simoens [Downloadable! (restricted)]
811-814 Funding a Clinical Trial: The Perspective of a Medicines Funder
by Peter Alsop & Scott Metcalfe & Jackie Evans [Downloadable! (restricted)]
815-830 Unrelated Medical Costs in Life-Years Gained: Should They be Included in Economic Evaluations of Healthcare Interventions?
by David R. Rappange & Pieter H.M. van Baal & N. Job A. van Exel & Talitha L. Feenstra & Frans F.H. Rutten & Werner B.F. Brouwer [Downloadable! (restricted)]
831-846 Quality-of-Life Assessment in Rheumatoid Arthritis
by Anthony S. Russell [Downloadable! (restricted)]
847-860 Multiple Sclerosis in the UK: Service Use, Costs, Quality of Life and Disability
by Paul McCrone & Margaret Heslin & Martin Knapp & Paul Bull & Alan Thompson [Downloadable! (restricted)]
861-877 Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland: An Analysis of the EUROPA Study Including 1251 Polish Patients
by W. Ken Redekop & Ewa Orlewska & Pawel Maciejewski & Frans F.H. Rutten & Louis W. Niessen [Downloadable! (restricted)]
879-889 Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with Standard Care in Elderly Patients with Heart Failure: An Individual Patient-Based Simulation Model
by Guiqing Yao & Nick Freemantle & Marcus Flather & Puvan Tharmanathan & Andrew Coats & Philip A. Poole-Wilson [Downloadable! (restricted)]
891-892 Assessing the Value of a Future Study
by Afschin Gandjour [Downloadable! (restricted)]
892-894 The Authors
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman [Downloadable! (restricted)]

2008, Volume 26, Issue 9

721-724 NICE's 2008 Methods Guide: Sensible Consolidation or Opportunities Missed?
by Mark Sculpher [Downloadable! (restricted)]
725-727 NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective
by Julia Earnshaw & Gavin Lewis [Downloadable! (restricted)]
729-732 NICE Methodology for Technology Appraisals: Cutting Edge or Tried and Trusted?
by Louise Longworth & Carole Longson [Downloadable! (restricted)]
733-744 The NICE Cost-Effectiveness Threshold: What it is and What that Means
by Christopher McCabe & Karl Claxton & Anthony J. Culyer [Downloadable! (restricted)]
745-751 Estimating `Costs' for Cost-Effectiveness Analysis
by Alec Miners [Downloadable! (restricted)]
753-767 Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
by Alex Sutton & A.E. Ades & Nicola Cooper & Keith Abrams [Downloadable! (restricted)]
769-779 Valuing Health States for Use in Cost-Effectiveness Analysis
by John Brazier [Downloadable! (restricted)]
781-798 Exploring Uncertainty in Cost-Effectiveness Analysis
by Karl Claxton [Downloadable! (restricted)]
799-806 Subgroups and Heterogeneity in Cost-Effectiveness Analysis
by Mark Sculpher [Downloadable! (restricted)]

2008, Volume 26, Issue 8

629-632 Waiting for Reimbursement of New Medicines in Canada: It's Time for a Rethink
by Brett J. Skinner [Downloadable! (restricted)]
633-648 Modelling Approaches: The Case of Schizophrenia
by Bart M.S. Heeg & Joep Damen & Erik Buskens & Sue Caleo & Frank de Charro & Ben A. van Hout [Downloadable! (restricted)]
649-659 Assessing the Impact of Global Price Interdependencies
by Anke Richter [Downloadable! (restricted)]
661-677 Conducting Discrete Choice Experiments to Inform Healthcare Decision Making: A User's Guide
by Emily Lancsar & Jordan Louviere [Downloadable! (restricted)]
679-697 Demand Forecasting for Preventive AIDS Vaccines: Economic and Policy Dimensions
by Robert Hecht & Gian Gandhi [Downloadable! (restricted)]
699-719 Trastuzumab: A Pharmacoeconomic Review of its Use in Early Breast Cancer
by Kate McKeage & Katherine A. Lyseng-Williamson [Downloadable! (restricted)]

2008, Volume 26, Issue 7

537-550 Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe
by Bjorn Wettermark & Brian Godman & Karolina Andersson & Lars L. Gustafsson & Alan Haycox & Vittorio Bertele' [Downloadable! (restricted)]
551-556 Pharmaceutical Risk-Sharing Agreements
by Joseph P. Cook & John A. Vernon & Richard Manning [Downloadable! (restricted)]
557-566 Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?
by Jon Jureidini & Barbara Mintzes & Melissa Raven [Downloadable! (restricted)]
567-568 The Author's Reply
by Adam E. Block [Downloadable! (restricted)]
569-587 Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes: A Systematic Review on Content and Adherence to Guidelines
by Stefan Vegter & Cornelis Boersma & Mark Rozenbaum & Bob Wilffert & GerJan Navis & Maarten J. Postma [Downloadable! (restricted)]
589-602 Future Drug Prices and Cost-Effectiveness Analyses
by Martin Hoyle [Downloadable! (restricted)]
603-616 Generic Entry, Reformulations and Promotion of SSRIs in the US
by Haiden A. Huskamp & Julie M. Donohue & Catherine Koss & Ernst R. Berndt & Richard G. Frank [Downloadable! (restricted)]
617-627 Cost-Effectiveness Analyses of Natalizumab (Tysabri(R)) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
by Ray Gani & Gavin Giovannoni & David Bates & Belinda Kemball & Steve Hughes & John Kerrigan [Downloadable! (restricted)]

2008, Volume 26, Issue 6

447-462 Economic Burden of Heart Failure in the Elderly
by Lawrence Liao & Larry A. Allen & David J. Whellan [Downloadable! (restricted)]
463-476 Cost of Epilepsy: A Systematic Review
by Adam Strzelczyk & Jens Peter Reese & Richard Dodel & Hajo M. Hamer [Downloadable! (restricted)]
477-495 Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
by Deborah A. Marshall & Patrick R. Douglas & Michael F. Drummond & George W. Torrance & Stuart MacLeod & Orlando Manti & Lokanadha Cheruvu & Ron Corvari [Downloadable! (restricted)]
497-511 Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model: Application to a Population of US Adult Smokers
by Paul Howard & Christopher Knight & Annabel Boler & Christine Baker [Downloadable! (restricted)]
513-536 Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
by Dirk Mueller & Eva Weyler & Afschin Gandjour [Downloadable! (restricted)]

2008, Volume 26, Issue 5

359-361 Cost-Effectiveness Analysis: Developing Nations Left Behind
by Mendel E. Singer [Downloadable! (restricted)]
363-370 Perspectives on Patient-Reported Outcomes: Content Validity and Qualitative Research in a Changing Clinical Trial Environment
by Nancy Kline Leidy & Margaret Vernon [Downloadable! (restricted)]
371-393 Economic Evaluation of Interventions to Treat Opiate Dependence: A Review of the Evidence
by Christopher M. Doran [Downloadable! (restricted)]
395-408 Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
by Nick Bansback & Roberta Ara & Jonathan Karnon & Aslam Anis [Downloadable! (restricted)]
409-423 Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making
by Lieven Annemans [Downloadable! (restricted)]
425-434 A Multicentre, Prospective Study to Evaluate Costs of Septic Patients in Brazilian Intensive Care Units
by Ana M.C. Sogayar & Flavia R. Machado & Alvaro Rea-Neto & Amselmo Dornas & Cintia M.C. Grion & Suzana M.A. Lobo & Bernardo R. Tura & Carla L.O. Silva & Ruy G.R. Cal & Idal Beer & Vilto Michels & Jorge Safi & Marcia Kayath & Eliezer Silva [Downloadable! (restricted)]
435-446 Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia
by Shelby D. Reed & Kevin J. Anstrom & Yanhong Li & Kevin A. Schulman [Downloadable! (restricted)]

2008, Volume 26, Issue 4

269-280 An Overview of Methods and Applications to Value Informal Care in Economic Evaluations of Healthcare
by Marc A. Koopmanschap & N. Job A. van Exel & Bernard van den Berg & Werner B.F. Brouwer [Downloadable! (restricted)]
281-296 Making a Case for Employing a Societal Perspective in the Evaluation of Medicaid Prescription Drug Interventions
by Sanjoy Roy & S. Suresh Madhavan [Downloadable! (restricted)]
297-310 The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4
by Paul A. Scuffham & Jennifer A. Whitty & Andrew Mitchell & Rosalie Viney [Downloadable! (restricted)]
311-328 Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model
by Simon Kreck & Jochen Klaus & Reiner Leidl & Christian von Tirpitz & Alexander Konnopka & Herbert Matschinger & Hans-Helmut Konig [Downloadable! (restricted)]
329-339 An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes
by Scott D. Ramsey & Lauren D. Clarke & Craig S. Roberts & Sean D. Sullivan & Scott J. Johnson & Larry Z. Liu [Downloadable! (restricted)]
341-358 Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study
by Martin Knapp & Frank Windmeijer & Jacqueline Brown & Stathis Kontodimas & Spyridon Tzivelekis & Josep Maria Haro & Mark Ratcliffe & Jihyung Hong & Diego Novick [Downloadable! (restricted)]

2008, Volume 26, Issue 3

179-180 Meandering Down the Road to Transparency
by Christopher I. Carswell & Joseph A. Paladino [Downloadable! (restricted)]
181-183 Transparency of Economic Evaluations of Health Technologies
by Joan Rovira [Downloadable! (restricted)]
185-189 Projecting Vaccine Efficacy: Accounting for Geographic Strain Variations
by Johnie Rose & Mendel E. Singer [Downloadable! (restricted)]
191-215 Cost-Effectiveness Analyses of Vaccination Programmes: A Focused Review of Modelling Approaches
by Sun-Young Kim & Sue J. Goldie [Downloadable! (restricted)]
217-234 Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
by Jeremy Chancellor & Samuel Aballea & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant [Downloadable! (restricted)]
235-249 Community and Patient Values for Preventing Herpes Zoster
by Tracy A. Lieu & Ismael Ortega-Sanchez & G. Thomas Ray & Donna Rusinak & W. Katherine Yih & Peter W. Choo & Irene Shui & Ken Kleinman & Rafael Harpaz & Lisa A. Prosser [Downloadable! (restricted)]
251-268 Zoledronic Acid: A Pharmacoeconomic Review of its Use in the Management of Bone Metastases
by Kate McKeage & Greg L. Plosker [Downloadable! (restricted)]

2008, Volume 26, Issue 2

91-98 Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies
by Brian Godman & Alan Haycox & Ulrich Schwabe & Roberta Joppi & Silvio Garattini [Downloadable! (restricted)]
99-120 Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents
by Mei Sheng Duh & Jennifer R. Weiner & Leigh Ann White & Patrick Lefebvre & Paul E. Greenberg [Downloadable! (restricted)]
121-129 Economic Burden of Psoriatic Arthritis
by Christoph Ackermann & Arthur Kavanaugh [Downloadable! (restricted)]
131-148 Modelling Methods for Pharmacoeconomics and Health Technology Assessment: An Overview and Guide
by James E. Stahl [Downloadable! (restricted)]
149-162 The Burden of Schizophrenia on Caregivers: A Review
by A. George Awad & Lakshmi N.P. Voruganti [Downloadable! (restricted)]
163-178 Non-Traditional Settings for Influenza Vaccination of Adults: Costs and Cost Effectiveness
by Lisa A. Prosser & Megan A. O'Brien & Noelle-Angelique M. Molinari & Katherine H. Hohman & Kristin L. Nichol & Mark L. Messonnier & Tracy A. Lieu [Downloadable! (restricted)]

2008, Volume 26, Issue 1

1-4 The New Myth: The Social Value of the QALY
by Werner Brouwer & Job van Exel & Rachel Baker & Cam Donaldson [Downloadable! (restricted)]
5-15 The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?
by Giovanni Fattore & Claudio Jommi [Downloadable! (restricted)]
17-32 Cost-Effectiveness Analyses of Hepatitis A Vaccine: A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies
by Andrea M. Anonychuk & Andrea C. Tricco & Chris T. Bauch & Ba' Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn [Downloadable! (restricted)]
33-44 Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas: A Cost-Utility Analysis
by Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville [Downloadable! (restricted)]
45-56 Dynamic Modelling of Infectious Diseases: An Application to the Economic Evaluation of Influenza Vaccination
by Roberto Pradas-Velasco & Fernando Antonanzas-Villar & Maria Puy Martinez-Zarate [Downloadable! (restricted)]
57-73 Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study
by Alan F. Cruess & Gergana Zlateva & Xiao Xu & Gisele Soubrane & Daniel Pauleikhoff & Andrew Lotery & Jordi Mones & Ronald Buggage & Caroline Schaefer & Tyler Knight & Thomas F. Goss [Downloadable! (restricted)]
75-90 Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections
by Robin de Vries & Simon Daenen & Keith Tolley & Axel Glasmacher & Archie Prentice & Sarah Howells & Hariette Christopherson & Lolkje T.W. de Jong-van den Berg & Maarten J. Postma [Downloadable! (restricted)]

2007, Volume 25, Issue 12

991-993 Acknowledgement
by Adis International Limited [Downloadable! (restricted)]
995-996 When NICE Says No!
by Alan Haycox [Downloadable! (restricted)]
997-1006 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used?
by Denis Getsios & Kristen Migliaccio-Walle & Jaime J. Caro [Downloadable! (restricted)]
1007-1029 Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX
by Katherine A. Lyseng-Williamson & Greg L. Plosker [Downloadable! (restricted)]
1031-1053 Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events
by Greg L. Plosker & Katherine A. Lyseng-Williamson [Downloadable! (restricted)]
1055-1062 Economic Evidence at the Local Level: Options for Making it More Useful
by Kees van Gool & Gisselle Gallego & Marion Haas & Rosalie Viney & Jane Hall & Robyn Ward [Downloadable! (restricted)]
1063-1082 Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events: An Assessment from the Payer's Perspective
by Bart Heeg & Joep Damen & Ben Van Hout [Downloadable! (restricted)]

2007, Volume 25, Issue 11

899-902 Warfarin Pharmacogenetics: Economic Considerations
by Dyfrig A. Hughes & Munir Pirmohamed [Downloadable! (restricted)]
903-911 It's Time to Choose the Study Design!: Net Benefit Analysis of Alternative Study Designs to Acquire Information for Evaluation of Health Technologies
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman [Downloadable! (restricted)]
913-933 The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A Structured Review of the Literature
by Rachael L. Fleurence & Cynthia P. Iglesias & Jeanene M. Johnson [Downloadable! (restricted)]
935-947 Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation: A Literature Review
by Alec H. Miners & Guiqing Yao & James Raftery & Rod S. Taylor [Downloadable! (restricted)]
949-961 Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia: A Cost-Effectiveness Analysis
by Amanda R. Patrick & Wolfgang C. Winkelmayer & Jerry Avorn & Michael A. Fischer [Downloadable! (restricted)]
963-977 Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B
by David L. Veenstra & Sean D. Sullivan & Lauren Clarke & Uche H. Iloeje & Eskinder Tafesse & Adrian Di Bisceglie & Kris V. Kowdley & Robert G. Gish [Downloadable! (restricted)]
979-990 The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary: Cost-Effectiveness and Budget-Impact Analyses
by Marcio Machado & Michael Iskedjian & Ines A. Ruiz & Thomas R. Einarson [Downloadable! (restricted)]

2007, Volume 25, Issue 10

807-816 Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions: Why Uncertainty About the Outcome, Estimate and Willingness to Pay Matters
by Jeffrey S. Hoch & Carolyn S. Dewa [Downloadable! (restricted)]
817-828 Valuing Children's Health: A Comparison of Cost-Utility Analyses for Adult and Paediatric Health Interventions in the US
by Joseph A. Ladapo & Peter J. Neumann & Ron Keren & Lisa A. Prosser [Downloadable! (restricted)]
829-841 A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
by Laura Bojke & Edward Hornby & Mark Sculpher [Downloadable! (restricted)]
843-862 Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
by Ya-Chen Tina Shih & Nebiyou B. Bekele & Ying Xu [Downloadable! (restricted)]
863-879 Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK
by Sorrel E. Wolowacz & Neil Roskell & Steven Kelly & Fiona M. Maciver & Chris S. Brand [Downloadable! (restricted)]
881-897 Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin: Economic Comparison in Adult and Adolescent Type 1 Diabetes Mellitus in Australia
by Neale Cohen & Michael E. Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William J. Valentine & Andrew J. Palmer [Downloadable! (restricted)]

2007, Volume 25, Issue 9

713-726 Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations
by Lisa A. Prosser & James K. Hammitt & Ron Keren [Downloadable! (restricted)]
727-734 The Increasingly Complex Fourth Hurdle for Pharmaceuticals
by Joshua Cohen & Elly Stolk & Maartje Niezen [Downloadable! (restricted)]
735-750 Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis
by Colin Green [Downloadable! (restricted)]
751-768 Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and Analysis of the Literature
by Andrew F. Shorr [Downloadable! (restricted)]
769-782 Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
by Bart M.S. Heeg & Ron J.G. Peters & Marc Botteman & Ben A. van Hout [Downloadable! (restricted)]
783-792 Preferences of Community Pharmacists for Extended Roles in Primary Care: A Survey and Discrete Choice Experiment
by Anthony Scott & Christine Bond & Jackie Inch & Aileen Grant [Downloadable! (restricted)]

More pages of listings: 0|1|2|3|4|5

Access and download statistics

Did you know? You too can volunteer for RePEc, for example by encouraging others to register as authors.

This page was last updated on 2009-11-13.

This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.